Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program

CONCLUSION: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines.PMID:38455882 | PMC:PMC10917417 | DOI:10.14745/ccdr.v49i78a07

Source: Can Commun Dis Rep - March 8, 2024 Category: Infectious Diseases Authors: Robyn Mitchell Diane Lee Linda Pelude Jeannette Comeau John Conly Chelsey Ellis Jennifer Ellison John Embil Gerald Evans Lynn Johnston Jennie Johnstone Kevin Katz Pamela Kibsey Bonita Lee Marie-Astrid Lefebvre Yves Longtin Allison McGeer Dominik Mertz Jes Source Type: research